SSKNのチャート
SSKNの企業情報
| symbol | SSKN |
|---|---|
| 会社名 | Strata Skin Sciences Inc （メラ・サイエンス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 ストラタ・スキン・サイエンス（Strata Skin Sciences Inc.）（旧名：MELA Sciences Inc.）は、医療機器会社である。同社は、皮膚がん早期検査のソフト駆動技術の設計・開発に従事する。同社は、皮膚病の再発性プログラム、皮膚病プログラムと皮膚病学検査という３つのセグメントにおいて運営する。同社の製品は、乾癬・白斑など様々な皮膚病の治療に使われるXTRACレーサー、VTRACエキシマ燈システムなどがある。また、同社は「MelaFind」という製品の商業化に集中する。「MelaFind」は黒色腫の診断に役立つ非侵襲性ポイント・オブ・ケア（医者のオフィスで）機器であい、多波長の光を発し、疑わしい色素性皮膚病変の画像を取り、データを抽出する手持ち式撮像装置である。そのデータは画像処理分類アルゴリズムを用いて、黒色腫と良性病変のデータベースに合わせて分析される。 メラ・サイエンスは、医療機器メ―カ―。同社製品は、黒色腫の検出を補助する器具｢MelaFind｣。｢MelaFind｣システムの構成要素は、光学系とマルチスペクトル照明を採用する手持ち部品、色素性皮膚病変のデ―タベ―ス、病変の特徴情報を抽出し分類する数学的アルゴリズムされている病変分類器などがある。 STRATA Skin Sciences is a medical technology company in dermatology and plastic surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. The Company's proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 35 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatment to vitiligo patients. STRATA's unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company's partner dermatology clinics. The XTRAC business has used this proven DTC model to grow its domestic dermatology partner network to over 832 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients an introduction to physicians prescribing a reimbursable solution, using XTRAC, within a 10-mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners. The Company has now introduced its Home by XTRAC™ business leveraging in-house resources including DTC advertising, in-house call center and its insurance reimbursement team to provide an at-home, insurance-reimbursed treatment option for patients with certain skin diseases that do not qualify for in-office treatments. |
| 本社所在地 | 100 Lakeside Drive Suite 100 Horsham PA 19044 USA |
| 代表者氏名 | LuAnn Via LuAnn Via |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 215-619-3200 |
| 設立年月日 | 32843 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 96人 |
| url | www.strataskinsciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sskn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 1.04900 |
| 終値（lastsale） | 3.2199 |
| 時価総額（marketcap） | 96413742.6114 |
| 時価総額 | 時価総額（百万ドル） 96.11731 |
| 売上高 | 売上高（百万ドル） 29.47400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 89.04531 |
| 当期純利益 | 当期純利益（百万ドル） 4.86500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 STRATA Skin Sciences Inc revenues decreased 11% to $14M. Net loss increased 4% to $3.6M. Revenues reflect Dermatology Recurring Procedures segment decrease of 62% to $4.5M Dermatology Procedures Equipment segment decrease of 51% to $2M United States (Country) segment decrease of 61% to $5.2M Foreign segment decrease of 51% to $1.3M. |
SSKNのテクニカル分析
SSKNのニュース
STRATA Skin Sciences, Inc.''s (SSKN) CEO Robert Moccia on Q4 2021 Results - Earnings Call Transcript 2022/03/21 22:11:05 Seeking Alpha
STRATA Skin Sciences GAAP EPS of -$0.02 beats by $0.01, revenue of $9.1M beats by $0.13M 2022/03/21 20:05:12 Seeking Alpha
STRATA Skin Sciences press release (SSKN): Q4 GAAP EPS of -$0.02 beats by $0.01.Revenue of $9.1M (+35.4% Y/Y) beats by $0.13M.Despite Omicron headwinds and insurance resets for the…
STRATA Skin Sciences Q4 2021 Earnings Preview (NASDAQ:SSKN) 2022/03/18 21:35:38 Seeking Alpha
STRATA Skin Sciences (SSKN) is scheduled to announce Q4 earnings results on Monday, March 21st, after market close.The consensus EPS Estimate is -$0.03 (-200.0% Y/Y) and the…
STRATA Skin Sciences rises 4% on distribution contract in Israel 2022/01/18 21:11:36 Seeking Alpha
STRATA Skin Sciences (SSKN) entered an agreement with JuvenIL, the dermatology and aesthetics portion of Trimaco, to supply STRATA’s XTRAC excimer lasers in Israel
STRATA Skin Sciences, Inc.''s (SSKN) CEO Robert Moccia on Q4 2021 Results - Earnings Call Transcript 2022/03/21 22:11:05 Seeking Alpha
STRATA Skin Sciences GAAP EPS of -$0.02 beats by $0.01, revenue of $9.1M beats by $0.13M 2022/03/21 20:05:12 Seeking Alpha
STRATA Skin Sciences press release (SSKN): Q4 GAAP EPS of -$0.02 beats by $0.01.Revenue of $9.1M (+35.4% Y/Y) beats by $0.13M.Despite Omicron headwinds and insurance resets for the…
STRATA Skin Sciences Q4 2021 Earnings Preview (NASDAQ:SSKN) 2022/03/18 21:35:38 Seeking Alpha
STRATA Skin Sciences (SSKN) is scheduled to announce Q4 earnings results on Monday, March 21st, after market close.The consensus EPS Estimate is -$0.03 (-200.0% Y/Y) and the…
STRATA Skin Sciences rises 4% on distribution contract in Israel 2022/01/18 21:11:36 Seeking Alpha
STRATA Skin Sciences (SSKN) entered an agreement with JuvenIL, the dermatology and aesthetics portion of Trimaco, to supply STRATA’s XTRAC excimer lasers in Israel
STRATA Skin Sciences rises 4% on distribution contract in Israel 2022/01/18 21:11:36 Seeking Alpha
STRATA Skin Sciences (SSKN) entered an agreement with JuvenIL, the dermatology and aesthetics portion of Trimaco, to supply STRATA’s XTRAC excimer lasers in Israel
STRATA Skin Sciences Acquires Theravant''s Acne Treatment Device, Expects Upside Q4 Sales 2022/01/11 11:43:09 Benzinga
STRATA Skin Sciences Inc (NASDAQ: SSKN ) expects Q4 FY21 sales of $8.8 million - $9.2 million , compared to $6.7 million in Q4 FY20 and the consensus of $8.19 million. For FY21, it expects sales of $29.7 million - $30.1 million (compared to a consensus of $29.11 million), up from $23.1 million in FY20. Cash and cash equivalents, including Full story available on Benzinga.com
STRATA Skin Sciences (NASDAQ:SSKN) Downgraded to D at TheStreet 2021/12/13 06:08:42 ETF Daily News
TheStreet downgraded shares of STRATA Skin Sciences (NASDAQ:SSKN) from a c- rating to a d rating in a research note issued to investors on Thursday, TheStreetRatingsTable reports. Separately, Zacks Investment Research raised shares of STRATA Skin Sciences from a sell rating to a hold rating in a report on Wednesday, August 18th. Shares of SSKN [] The post STRATA Skin Sciences (NASDAQ:SSKN) Downgraded to D at TheStreet appeared first on ETF Daily News .
STRATA Skin Sciences Announces Board of Directors Transition 2021/12/09 21:01:00 Intrado Digital Media
HORSHAM, Pa., Dec. 09, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that Douglas Strang was appointed to the Board of Directors, effective October 27, 2021. Mr. Strang will assume the role of Audit Committee Chair upon the departure of LuAnn Via, who will step down from the Board on December 31, 2021 as part of a planned transition.
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Short Interest Update 2021/11/19 10:38:41 Dakota Financial News
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) was the target of a significant decline in short interest in October. As of October 29th, there was short interest totalling 19,800 shares, a decline of 33.3% from the October 14th total of 29,700 shares. Based on an average daily trading volume, of 70,200 shares, the days-to-cover ratio is presently []